Viewing Study NCT03469895


Ignite Creation Date: 2025-12-24 @ 1:37 PM
Ignite Modification Date: 2026-01-02 @ 6:49 AM
Study NCT ID: NCT03469895
Status: UNKNOWN
Last Update Posted: 2018-03-19
First Post: 2018-03-05
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Autoimmune Cytopenia and BcR Inhibitors
Sponsor: Institut Paoli-Calmettes
Organization:

Study Overview

Official Title: Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)
Status: UNKNOWN
Status Verified Date: 2018-03
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CABRI
Brief Summary: Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)
Detailed Description: The investigators of the study propose a card of data collection, validated by the scientific council of the group FILO.

The data to be collected are entered on an e-CRF made available to the investigators on a secure site.

The main data collected are as follows

* anonymized demographic data
* Clinical and Biological Data of CLL at Diagnosis
* Previous treatments of LLC and CAI
* clinical and laboratory data at the time of initiation of BCRi treatment
* response to treatment with BCRi
* tolerance to BCRi treatment
* Progression under treatment with BCRi
* Recent news

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: